Breast Cancer Index
www.breastcancerindex.comThe only commercially available, validated genomic test that predicts whether a woman with early-stage HR+ breast cancer is likely to benefit from anti-estrogen therapy beyond 5 years and her individual risk of recurrence between 5 and 10 years.
Read more
The only commercially available, validated genomic test that predicts whether a woman with early-stage HR+ breast cancer is likely to benefit from anti-estrogen therapy beyond 5 years and her individual risk of recurrence between 5 and 10 years.
Read more
Country
State
California
City (Headquarters)
San Diego
Industry
Founded
2008
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Marketing Associate
Email ****** @****.comPhone (***) ****-****
Technologies
(45)
Reach decision makers at Breast Cancer Index
Free credits every month!
Breast Cancer Index FAQ
San Diego, United States
Biotechnology Research
